Marksans vigorously pursues an inorganic expansion strategy, actively engaged in the identification, evaluation, and acquisition of significant global businesses. This strategic approach aims to confer a competitive advantage by broadening our product portfolio and establishing a foothold in critical global markets.
In 2005, Marksans acquired a 60% stake in Nova Australasia Pty Ltd. (Nova), an Australian marketing company that specializes in marketing OTC and pharmaceutical products. Nova primarily focuses on Analgesics, Antihistamines, Anti-fungal, Anti-Allergy, Dermatology, Essential Oils, and Gastrointestinal segments.
The company has robust operating margins and a presence across top pharmacies and major chain stores for the distribution of generics and OTC products. The company now has over 100 products in its portfolio with another 25 products awaiting TGA approvals.
Bell, Sons & Co. (Druggists) Ltd
In 2008, Marksans acquired UK's Hale Group along with its subsidiary company Bell, Sons & Co. (Druggists) Ltd. (Bell). Bell’s manufactures licensed products - both as own-branded products and, for certain customers, in private-label form together with a range of other products. It is the largest manufacturer of private-label and branded cough liquids in the UK.
The company owns a state-of-the-art manufacturing facility in Southport and is an established manufacturer of over 200 OTC pharmaceuticals having full approval of the UK MHRA. It manufactures more than 450 SKUs across cough and cold, pain management, gastrointestinal, vitamins, palliative healthcare products, and oils.
The company enjoys a significant stronghold in the export markets. With more than 80 years of experience and a reach across 50+ countries, the brand is recognized and respected globally. Its key markets are West Africa and the Middle East.
In August 2008, Marksans acquired Relonchem Ltd. The company is engaged in licensing, marketing, and distribution of prescription generic pharmaceutical products to wholesalers, retailers, and hospitals in the UK.
With these successful consolidation activities, Marksans has the potential to grow significantly due to a wider product portfolio, better market access, and comprehensive R&D capabilities.
The company’s portfolio includes own-label products in therapies such as anti-diabetic, anti-hypertensive, anti-depressant, anti-cancer, anti-ulcerative, anti-allergic, hormones, steroids, and pain relief for the UK market.
Time Cap Labs Inc.
In 2015, Marksans acquired Time Cap Labs Inc., a significant move towards enhancing its presence in the US markets. With USA constituting 30-40% of the global pharmaceutical market, this acquisition has been a huge boon.
Time Cap Labs focuses on manufacturing high-quality products in both OTC and prescription markets across pain management, cough and cold, digestive, allergy, CVS, CNS, and anti-diabetic segments.
In the year 2022, Marksans acquired a 100% stake in Dubai-based Access Healthcare for Medical Products L.L.C. This deal bolsters their presence in the Middle East and North African regions by leveraging Access Health’s knowledge of local business cultures and access to a network of partners and distributors in those regions.
Marksans Pharma completes the acquisition from Tevapharm India, expanding the existing manufacturing capacity in India
Marksans Pharma Ltd. (NSE: MARKSANS; BSE:524404), one of the fastest-growing pharmaceutical companies in India, has completed the acquisition of a manufacturing site from Tevapharm India in Plot No. Al, Phase l-A, Verna Industrial Estate, Verna, Goa 403722, India. The acquisition was first announced in October 2022.